CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 180 enrolled
Drug / intervention
Testosterone gel (FE 999303)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01665599
NCT01665599Phase 3Completed
CompareCT.gov

A Phase 3, Open-label, Non-randomized, Clinical Trial to Evaluate the Efficacy and Safety of FE 999303 (Testosterone Gel) in Adult Hypogonadal Males

Ferring Pharmaceuticals·interventional·Posted Aug 15, 2012·Updated Oct 26, 2017

In Brief

A Phase 3 clinical trial evaluating Testosterone gel (FE 999303) for Adult Male Hypogonadism. Completed, enrolled 180 participants across 19 sites in 2 countries.

Detailed Summary

This is a Phase 3 clinical trial in adult hypogonadal males with baseline serum testosterone concentrations \<300 ng/dL. The purpose of this study is to evaluate the safety and efficacy of testosterone gel (2%) delivered using an applicator.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Male Hypogonadism
CountriesCanada, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 15, 2012
Enrollment StartJul 1, 2012
Primary CompletionApr 1, 2013
Study CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 13.9 years ago

Interventions

Testosterone gel (FE 999303)drug